文献速递腹部技术与安全MR

LI-RADS 2018版、LI-RADS 2017版与OPTN标准对肝细胞癌的诊断效能

Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma.
PubMed 文献 · AJR Am J Roentgenol · 2020-09-02

回顾性纳入122例患者159个观察灶,比较MRI上LI-RADSv2018、LI-RADSv2017与OPTN标准诊断肝细胞癌的效能。LI-RADSv2018的LR-5及LR-TIV+5敏感度显著高于v2017(63.9% vs 55.2%,p=0.008)和OPTN class 5(63.9% vs 53.6%,p=0.004),特异度均无差异(97.3% vs 97.3%,p=1.00)。

要点

  • LI-RADSv2018将v2017的8个LR-4观察灶重分类为LR-5,均为肝细胞癌。
  • LI-RADSv2018将v2017的6个LR-4观察灶重分类为LR-3,均为非肝细胞癌。
  • LI-RADSv2018的LR-5及LR-TIV+5敏感度高于OPTN class 5,特异度无差异。

核心结论

  • LI-RADSv2018诊断肝细胞癌的效能高于LI-RADSv2017和OPTN标准,表现为敏感度更高而特异度相似。

研究设计与样本

  • 回顾性研究纳入122例患者共159个观察灶,均符合LI-RADS肝细胞癌风险标准,且有2015年1月1日至2018年1月1日期间的至少一次肝脏MRI观察。
  • 参考标准为组织病理学结果(n=104)或随访影像(n=55)。
  • 三名腹部放射科医师独立并共识使用LI-RADSv2017、LI-RADSv2018和OPTN标准分配类别,采用广义估计方程比较诊断效能。

诊断标准与关键数值

  • 基于LI-RADSv2018的LR-5及LR-TIV+5(即LR-TIV[癌栓]明确由肝细胞癌所致)诊断肝细胞癌的敏感度为63.9%,特异度为97.3%。
  • 基于LI-RADSv2017的LR-5及LR-TIV+5诊断肝细胞癌的敏感度为55.2%,特异度为97.3%。
  • OPTN class 5标准诊断肝细胞癌的敏感度为53.6%,特异度为97.3%。
  • LI-RADSv2018的LR-5及LR-TIV+5敏感度显著高于LI-RADSv2017(63.9% vs 55.2%,p=0.008),特异度无差异(97.3% vs 97.3%,p=1.00)。
  • LI-RADSv2018的LR-5及LR-TIV+5敏感度显著高于OPTN class 5(63.9% vs 53.6%,p=0.004),特异度无差异(97.3% vs 97.3%,p=1.00)。

临床应用与阅片要点

  • 在MRI阅片和报告中使用LI-RADSv2018的LR-5及LR-TIV+5类别诊断肝细胞癌,较v2017和OPTN class 5标准可提高敏感度且不降低特异度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE. Liver Imaging Reporting and Data System (LI-RADS) was updated in 2018 (LI-RADS version 2018 [LI-RADSv2018]) to facilitate integration into the American Association for the Study of Liver Diseases 2018 clinical practice guidelines and involved changes in LR-5 categorization and threshold growth definitions. There are also differences between the criteria for LI-RADSv2018 LR-5 category and the criteria for Organ Procurement and Transplantation Network (OPTN) class 5. The objective of our study was to compare the diagnostic performances of LI-RADSv2018, LI-RADS version 2017 (LI-RADSv2017), and OPTN criteria for diagnosing hepatocellular carcinoma (HCC) on MRI. MATERIALS AND METHODS. In this retrospective study, 122 patients with 159 observations were included who met LI-RADS criteria for at risk for HCC and had at least one hepatic observation on MRI performed between January 1, 2015, and January 1, 2018 and who had histopathology results (n = 104) or follow-up imaging (n = 55) as reference standards. Three abdominal radiologists assigned categories independently and in consensus using LI-RADSv2017, LI-RADSv2018, and OPTN criteria. Diagnostic performance was compared among the guidelines with a generalized estimating equation. RESULTS. Fourteen of 159 (8.8%) observations were assigned a different category according to LI-RADSv2018 compared with LI-RADSv2017. Eight of 31 (25.8%) LR-4 observations using v2017 were recategorized as LR-5 using v2018, and all eight were HCC. Six of 31 (19.4%) LR-4 observations based on v2017 were recategorized as LR-3 using v2018, and all six were non-HCCs. Seven of 114 (6.1%) observations not meeting OPTN class 5 criteria were LR-5 using v2018, and all seven were HCC. Sensitivity for HCC of LR-5 and LR-TIV+5 (i.e., LR-TIV [tumor in vein] definitely due to HCC) categories based on v2018 was significantly higher than that based on v2017 (63.9% vs 55.2%, respectively; p = 0.008) without a difference in specificity (97.3% vs 97.3%; p = 1.00). Sensitivity of LR-5 and LR-TIV+5 in LI-RADSv2018 was significantly higher than the sensitivity of class 5 in OPTN criteria (63.9% vs 53.6%; p = 0.004) without a difference in specificity (97.3% vs 97.3%; p = 1.00). Reader agreement was moderate for overall LIRADSv2017 and LI-RADSv2018 categories (κ = 0.504 and 0.561, respectively); substantial for LR-5 and LR-TIV+5 categories as diagnostic of HCC versus other categories for both v2017 and v2018 (κ = 0.758 and 0.802, respectively); and substantial for OPTN class 5 criteria (κ = 0.756). CONCLUSION. The diagnostic performance of LI-RADSv2018 is higher, with higher sensitivity and similar specificity, than the diagnostic performance of LI-RADSv2017 and OPTN criteria for HCC.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Kierans AS, Song C, Gavlin A, et al. Diagnostic Performance of LI-RADS Version 2018, LI-RADS Version 2017, and OPTN Criteria for Hepatocellular Carcinoma. AJR Am J Roentgenol. 2020. PMID: 32877248. doi:10.2214/AJR.20.22772

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。